Anti-tumour necrosis factor therapy ameliorates joint disease in a chronic model of inflammatory arthritis

Br J Rheumatol. 1997 Oct;36(10):1129. doi: 10.1093/rheumatology/36.10.1129.
No abstract available

Publication types

  • Letter

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Cricetinae
  • Disease Models, Animal
  • Immunoglobulin G / administration & dosage
  • Immunoglobulin G / immunology
  • Immunoglobulin G / therapeutic use
  • Immunosuppressive Agents
  • Incidence
  • Injections, Intraperitoneal
  • Joint Diseases / chemically induced
  • Joint Diseases / drug therapy*
  • Joint Diseases / prevention & control
  • Knee Joint / pathology
  • Knee Joint / physiopathology
  • Mice
  • Mice, Inbred DBA
  • Severity of Illness Index
  • Terpenes
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Terpenes
  • Tumor Necrosis Factor-alpha
  • pristane